NCT05683704View on ClinicalTrials.gov

Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

May 31, 2024

Study Completion Date

May 31, 2026

Conditions
Recurrent/Refractory Classical Hodgkin's Lymphoma
Interventions
DRUG

AK105，Anrotinib hydrochloride

AK105 administered IV at day 1 every 3 weeks for 8-12 cycles Anrotinib administered PO at day 1-14 every 3 weeks for 8-12 cycles

Trial Locations (1)

300060

Tianjin Medical University Cancer Insititute & Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER